Pasar al contenido principal

ABORDAJES TERAPEUTICOS EN LEUCEMIA MIELOIDE CRONICA MEDIANTE CRISPR/CAS9

PI17/01895

•
Nombre agencia financiadora Instituto de Salud Carlos III
Acrónimo agencia financiadora ISCIII
Programa Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de Investigación en Salud
Año convocatoria 2017
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION INSTITUTO DE ESTUDIOS DE CIENCIAS DE LA SALUD DE CASTILLA Y LEON
Centro realización INSTITUTO DE INVESTIGACION BIOMEDICA DE SALAMANCA (IBSAL)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity

  • van der Lee, Sven J.|||0000-0003-1606-8643
  • Conway, Olivia J.
  • Jansen, Iris E.|||0000-0003-1901-8131
  • Carrasquillo, Minerva M.
  • Kleineidam, Luca
  • van den Akker, Erik
  • Hernández, Isabel|||0000-0001-8119-393X
  • Van Eijk, Kristel R.
  • Stringa, Najada|||0000-0001-6350-452X
  • Chen, Jason A.
  • Zettergren, Anna|||0000-0002-7182-8417
  • Andlauer, Till F. M.|||0000-0002-2917-5889
  • Diez-Fairen, Monica|||0000-0003-1882-0309
  • Simón Sánchez, Javier|||0000-0001-5141-5829
  • Lleó, Alberto|||0000-0002-2568-5478
  • Zetterberg, Henrik|||0000-0003-3930-4354
  • Nygaard, Marianne|||0000-0003-0703-2665
  • Blauwendraat, Cornelis|||0000-0001-9358-8111
  • Savage, Jeanne E.
  • Mengel-From, Jonas
  • Moreno-Grau, Sonia
  • Wagner, Michael
  • Fortea, Juan|||0000-0002-1340-638X
  • Keogh, Michael J.
  • Blennow, Kaj|||0000-0002-1890-4193
  • Skoog, Ingmar
  • Friese, Manuel A.
  • Pletnikova, Olga|||0000-0001-6516-4944
  • Zulaica, Miren
  • Lage, Carmen|||0000-0003-1703-121X
  • De Rojas, Itziar|||0000-0002-2148-381X
  • Riedel-Heller, Steffi|||0000-0003-4321-6090
  • Illán-Gala, Ignacio|||0000-0002-5418-2052
  • Wei, Wei
  • Jeune, Bernard
  • Orellana del Río, Adelina|||0000-0002-0204-1944
  • Then Bergh, Florian
  • Wang, Xue
  • Hulsman, Marc|||0000-0002-9889-3606
  • Beker, Nina
  • Tesi, Niccolo|||0000-0002-1413-5091
  • Morris, Christopher M.
  • Indakoetxea, Begoña
  • Collij, Lyduine E.
  • Scherer, Martin
  • Morenas-Rodríguez, Estrella|||0000-0002-7591-6051
  • Ironside, James W.
  • van Berckel, Bart N. M.
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Wiendl, Heinz|||0000-0003-4310-3432
  • Strickland, Samantha L.
  • Pastor, Pau|||0000-0002-7493-8777
  • Rodríguez-Rodríguez, Eloy|||0000-0001-7742-677X
  • Boeve, Bradley
  • Petersen, Ronald C.
  • Ferman, Tanis J.
  • van Gerpen, Jay A.
  • Reinders, Marcel J. T.|||0000-0002-1148-1562
  • Uitti, Ryan J.
  • Tárraga, Lluís|||0000-0002-8423-946X
  • Maier, Wolfgang
  • Dols Icardo, Oriol|||0000-0003-2656-8748
  • Kawalia, Amit
  • Dalmasso, Maria Carolina|||0000-0002-4901-9955
  • Boada, Mercè|||0000-0003-2617-3009
  • Zettl, Uwe K.
  • van Schoor, Natasja M.
  • Beekman, Marian|||0000-0003-0585-6206
  • Allen, Mariet
  • Masliah, Eliezer
  • de Munain, Adolfo López
  • Pantelyat, Alexander
  • Wszolek, Zbigniew K.|||0000-0001-5487-1053
  • Ross, Owen A.|||0000-0003-4813-756X
  • Dickson, Dennis W.|||0000-0001-7189-7917
  • Graff-Radford, Neill R.
  • Knopman, David
  • Rademakers, Rosa
  • Lemstra, Afina W.|||0000-0002-8933-3260
  • Pijnenburg, Yolande|||0000-0003-2464-1905
  • Scheltens, Philip|||0000-0002-1046-6408
  • Gasser, Thomas|||0000-0003-4882-2647
  • Chinnery, Patrick F.
  • Hemmer, Bernhard|||0000-0001-5985-6784
  • Huisman, Martijn A.
  • Troncoso, Juan
  • Moreno, Fermin|||0000-0001-5200-3164
  • Nohr, Ellen A.
  • Sørensen, Thorkild I. A.|||0000-0003-4821-430X
  • Heutink, Peter|||0000-0001-5218-1737
  • Sánchez-Juan, Pascual|||0000-0002-6081-8037
  • Posthuma, Danielle|||0000-0001-7582-2365
  • Clarimón, Jordi|||0000-0002-6824-6942
  • Christensen, Kaare|||0000-0002-5429-5292
  • Ertekin-Taner, Nilüfer
  • Scholz, Sonja|||0000-0002-6623-0429
  • Ramirez, Alfredo|||0000-0003-4991-763X
  • Ruiz Laza, Agustín|||0000-0003-2633-2495
  • Slagboom, Eline
  • van der Flier, Wiesje M.|||0000-0001-8766-6224
  • Holstege, Henne|||0000-0002-7688-3087
The genetic variant rs72824905-G (minor allele) in the PLCG2 gene was previously associated with a reduced Alzheimer's disease risk (AD). The role of PLCG2 in immune system signaling suggests it may also protect against other neurodegenerative diseases and possibly associates with longevity. We studied the effect of the rs72824905-G on seven neurodegenerative diseases and longevity, using 53,627 patients, 3,516 long-lived individuals and 149,290 study-matched controls. We replicated the association of rs72824905-G with reduced AD risk and we found an association with reduced risk of dementia with Lewy bodies (DLB) and frontotemporal dementia (FTD). We did not find evidence for an effect on Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS) risks, despite adequate sample sizes. Conversely, the rs72824905-G allele was associated with increased likelihood of longevity. By-proxy analyses in the UK Biobank supported the associations with both dementia and longevity. Concluding, rs72824905-G has a protective effect against multiple neurodegenerative diseases indicating shared aspects of disease etiology. Our findings merit studying the PLCγ2 pathway as drug-target.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Agreement of amyloid PET and CSF biomarkers for Alzheimer's disease on Lumipulse

  • Alcolea, Daniel|||0000-0002-3819-3245
  • Pegueroles, Jordi|||0000-0002-3554-2446
  • Muñoz, Laia|||0000-0003-0578-3094
  • Camacho, Valle|||0000-0003-0748-0847
  • Lopez Mora, Diego Alfonso|||0000-0002-3533-7362
  • Fernández León, Alejandro|||0000-0002-1010-9451
  • Le Bastard, Nathalie
  • Huyck, Else
  • Nadal, Alicia
  • Olmedo, Verónica
  • Sampedro, Frederic|||0000-0002-3933-1355
  • Montal, Victor|||0000-0002-5714-9282
  • Vilaplana, Eduard|||0000-0002-1809-8435
  • Clarimón, Jordi|||0000-0002-6824-6942
  • Blesa, Rafael|||0000-0003-4026-2884
  • Fortea, Juan|||0000-0002-1340-638X
  • Lleó, Alberto|||0000-0002-2568-5478
To determine the cutoffs that optimized the agreement between 18 F-Florbetapir positron emission tomography (PET) and A β 1-42, A β 1-40, tTau, pTau and their ratios measured in cerebrospinal fluid (CSF) on the LUMIPULSE G600II instrument, we quantified the levels of these four biomarkers in 94 CSF samples from participants of the Sant Pau Initiative on Neurodegeneration (SPIN cohort) using the Lumipulse G System with available 18 F-Florbetapir imaging. Participants had mild cognitive impairment (n = 35), AD dementia (n = 12), other dementias or neurodegenerative diseases (n = 41), or were cognitively normal controls (n = 6). Levels of A β 1-42 were standardized to certified reference material. Amyloid scans were assessed visually and through automated quantification. We determined the cutoffs of CSF biomarkers that optimized their agreement with 18 F-Florbetapir PET and evaluated concordance between markers of the amyloid category. A β 1-42, tTau and pTau (but not A β 1-40) and the ratios with A β 1-42 had good diagnostic agreement with 18 F-Florbetapir PET. As a marker of amyloid pathology, the A β 1-42/A β 1-40 ratio had higher agreement and better correlation with amyloid PET than A β 1-42 alone. CSF biomarkers measured with the Lumipulse G System show good agreement with amyloid imaging in a clinical setting with heterogeneous presentations of neurological disorders. Combination of A β 1-42 with A β 1-40 increases the agreement between markers of amyloid pathology.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Cerebrospinal fluid profile of NPTX2 supports role of Alzheimer's disease-related inhibitory circuit dysfunction in adults with down syndrome

  • Belbin, Olivia|||0000-0002-6109-6371
  • Xiao, M.F.
  • Xu, D.
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Pegueroles, Jordi|||0000-0002-3554-2446
  • Benejam, Bessy|||0000-0002-6789-8615
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Fernández, S.
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Núñez-Llaves, Raúl|||0000-0002-6702-4774
  • Montal, Victor|||0000-0002-5714-9282
  • Vilaplana, Eduard|||0000-0002-1809-8435
  • Altuna-Azkargorta, Miren|||0000-0001-9709-5314
  • Clarimón, Jordi|||0000-0002-6824-6942
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Blesa, Rafael|||0000-0003-4026-2884
  • Lleó, Alberto|||0000-0002-2568-5478
  • Worley, P.F.
  • Fortea, Juan|||0000-0002-1340-638X
Alzheimer's disease (AD) is the major cause of death in adults with Down syndrome (DS). There is an urgent need for objective markers of AD in the DS population to improve early diagnosis and monitor disease progression. NPTX2 has recently emerged as a promising cerebrospinal fluid (CSF) biomarker of Alzheimer-related inhibitory circuit dysfunction in sporadic AD patients. The objective of this study was to evaluate NPTX2 in the CSF of adults with DS and to explore the relationship of NPTX2 to CSF levels of the PV interneuron receptor, GluA4, and existing AD biomarkers (CSF and neuroimaging). This is a cross-sectional, retrospective study of adults with DS with asymptomatic AD (aDS, n = 49), prodromal AD (pDS, n = 18) and AD dementia (dDS, n = 27). Non-trisomic controls (n = 34) and patients with sporadic AD dementia (sAD, n = 40) were included for comparison. We compared group differences in CSF NPTX2 according to clinical diagnosis and degree of intellectual disability. We determined the relationship of CSF NPTX2 levels to age, cognitive performance (CAMCOG, free and cued selective reminding, semantic verbal fluency), CSF levels of a PV-interneuron marker (GluA4) and core AD biomarkers; CSF Aβ1-42, CSF t-tau, cortical atrophy (magnetic resonance imaging) and glucose metabolism ([18F]-fluorodeoxyglucose positron emission tomography). Compared to controls, mean CSF NPTX2 levels were lower in DS at all AD stages; aDS (0.6-fold, adj.p < 0.0001), pDS (0.5-fold, adj.p < 0.0001) and dDS (0.3-fold, adj.p < 0.0001). This reduction was similar to that observed in sporadic AD (0.5-fold, adj.p < 0.0001). CSF NPTX2 levels were not associated with age (p = 0.6), intellectual disability (p = 0.7) or cognitive performance (all p.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Obesity and Alzheimer's disease, does the obesity paradox really exist? A magnetic resonance imaging study

  • Pegueroles, Jordi|||0000-0002-3554-2446
  • Jiménez Pineda, Amanda|||0000-0003-4967-1174
  • Vilaplana, Eduard|||0000-0002-1809-8435
  • Montal, Victor|||0000-0002-5714-9282
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Pané, Adriana|||0000-0002-7810-1827
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Casajoana, Anna
  • Clarimón, Jordi|||0000-0002-6824-6942
  • Ortega, Emilio|||0000-0002-2217-8905
  • Vidal, Josep|||0000-0002-4564-4518
  • Blesa, Rafael|||0000-0003-4026-2884
  • Lleó, Alberto|||0000-0002-2568-5478
  • Fortea, Juan|||0000-0002-1340-638X
Mid-life obesity is an established risk factor for Alzheimer's disease (AD) dementia,whereas late-life obesity has been proposed as a protective state. Weight loss, whichpredates cognitive decline, might explain this obesity paradox on AD risk. We aimedto assess the impact of late life obesity on brain structure taking into account weightloss as a potential confounder. We included 162 elderly controls of the Alzheimer'sDisease Neuroimaging Initiative (ADNI) with available 3T MRI scan. Significant weightloss was defined as relative weight loss =5% between the baseline and last followup visit. To be able to capture weight loss, only subjects with a minimum clinical andanthropometrical follow-up of 12 months were included. Individuals were categorizedinto three groups according to body mass index (BMI) at baseline: normal-weight(BMI<25 Kg/m), overweight (BMI 25-30 Kg/m) and obese (BMI.